Drugs / LPM3770164
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07516899 | Apr → Jun 2026 overdue | Huntington disease | Luye Pharma Group Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06474650 | Jul → Sep 2024 | Huntington disease, tardive dyskinesia | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06216054 | Dec 2023 → Jul 2024 | Huntington disease, tardive dyskinesia | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05238701 | Feb 2022 → Nov 2023 | Huntington disease, tardive dyskinesia | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06731868 | Jan → Oct 2025 overdue | tardive dyskinesia | Luye Pharma Group Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPM3770164 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06474650 ↗ |
| Route | Oral | “administrated orally single-dose on day 1” NCT05238701 ↗ |